For Immediate Release
Chicago, IL - February 7, 2024 - Today, Zacks Investment Ideas feature highlights Vertiv VRT, CrowdStrike CRWD, and Arista Networks ANET.
3 Buy-Rated Stocks Outperforming the Magnificent 7
The Magnificent 7 (Apple, Meta Platforms, Alphabet, Microsoft, Tesla, NVIDIA, and Amazon) group has been the dominant story of the market for some time now, performing remarkably and providing stellar gains. They’ve led the market, with recent quarterly results from a few members adding further excitement and extending the positive price action.
Thanks to their dominant market stance, outperforming the group has been nearly impossible. However, that certainly hasn’t been the case for all, including Vertiv, CrowdStrike, and Arista Networks.
All three stocks have outperformed the Magnificent 7 as a group over the last year.
In addition, all three sport a favorable Zacks Rank, reflecting upward trending earnings estimate revisions. For those seeking to outperform the market titans, let’s take a closer look at each.
Arista Networks
Arista Networks, a Zacks Rank #1 (Strong Buy), is an industry leader in data-driven, client-to-cloud networking for large data centers, campus, and routing environments. The revisions trend has been particularly bullish for its current fiscal year outlook, up 13% to $6.55 per share over the last year.
The company’s quarterly consistency can’t be overlooked, exceeding both top and bottom line consensus expectations in each of its last ten releases. The company’s top line has enjoyed significant expansion over the last few quarters thanks to customer momentum in both enterprise and cloud/AI sectors.
Keep an eye out for the company’s next quarterly release scheduled for February 12th, as current consensus expectations currently suggest 21% earnings growth on 20% higher sales. Analysts have taken their bottom line expectations modestly higher since last November.
CrowdStrike
CrowdStrike, a current Zacks Rank #1 (Strong Buy), is a leader in next-generation endpoint protection, threat intelligence, and cyberattack response services. Like ANET, the revisions trend for CrowdStrike’s current fiscal year has been robust, up 46% to $2.95 per share over the last year.
The stock remains a prime consideration for growth investors, currently carrying a Style Score of ‘A’ for Growth. Consensus expectations for its current fiscal year suggest 90% earnings growth paired with a sizable 36% revenue climb.
CrowdStrike’s latest set of quarterly results had shares moving higher post-earnings, with the company delivering record profitability and record free cash flow. Annual recurring revenue also showed considerable growth, improving 35% year-over-year.
Shares have jumped higher post-earnings in back-to-back releases.
Vertiv
Vertiv, a current Zacks Rank #2 (Buy), is a global leader in designing, building, and servicing critical infrastructure that enables vital applications for data centers. The company is the only pure-play data center infrastructure provider able to deliver across the entire spectrum of thermal and power technologies.
Shares aren’t valuation stretched given the company’s forecasted growth, with shares currently trading at a 27.1X forward earnings multiple (F1). Consensus expectations for its current year allude to a 220% pop in earnings on 21% higher sales.
The company’s top line expansion has already been impressive, posting double-digit percentage year-over-year revenue growth rates in six consecutive quarterly releases.
Vertiv will deliver its next set of quarterly results on February 21st. Current consensus expectations suggest 90% earnings growth and 14% expansion across the top line. Shares have moved higher post-earnings in three consecutive releases.
Bottom Line
While most market headlines are centered around the Magnificent 7 group, investors may be surprised to learn that there have been other stocks delivering even stronger gains.
All three stocks above have precisely done that, delivering ‘Mag 7-beating’ gains over the last year.
In addition, all three sport favorable Zacks Ranks, with upwards trending earnings estimate revisions helping drive the moves.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
*Zacks Names "Single Best Pick to Double"
*From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
*It’s credited with a "watershed medical breakthrough" and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
*It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up